Skip to main content

Cardiff Oncology, Inc 8-K, filed Nov 12, 2026

Cardiff Oncology, Inc. (CRDF)

8-K 2026-11-12 For: 2026-11-10
View Original
Added on November 13, 2026

About this 8-K

Cardiff Oncology, Inc filed this 8-K on November 12, 2026, reporting on events of November 10, 2026.

Cardiff Oncology reported that median PFS has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm versus approximately 11 months in combined standard-of-care arms. It is preparing a registrational Phase 3 trial with a potential Q1 2027 start. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits